IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Douglas Craig HOOPER, et al.

Application No.:

10/560,299

(International Application No. PCT/US2004/018613)

Filed:

(International Filing Date: 10 June 2004 (10.06.2004))

For:

RECOMBINANT ANTIBODIES AND COMPOSITIONS AND

METHODS FOR MAKING AND USING THE SAME

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying form PTO-1449, except for any U.S. patents and published U.S. patent applications which may be listed.

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

> CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label No:

Date of Deposit:

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

> Heriae signature of person mailing page:

Type or print name of person

PHIP\482456\1

This Information Disclosure Statement should not be construed as a representation that the cited references are material or prior art, or that more relevant references do not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

Douglas Craig HOOPER, et al.

BY

DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3312

TEL: (215) 988-3312 FAX: (215) 988-2757 Attorney for Applicants **SUBSTITUTE FORM PTO-1449**

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 8321-221US

Int.'l. App. No.:

INFORMATION DISCLOSURE STATEMENT

PCT/US2004/018613

APPLICANT:

Douglas C. Hooper et al.

Int.'l. Filing Date:

GROUP

10 June 2004

Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	US 6,890,532	05/10/2005	Hooper et al.	424	147.1	
	AB	US 2003/0157112	08/21/2003	Hooper et al.	424	159.1	
	AC	US 2003/0165507	09/04/2003	Hooper et al.	424	147.1	
	AD	US 2004/0013672	01/22/2004	Hooper et al.	424	159.1	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL. YES	ATION NO
AE	WO 93/21319	10/28/1993	PCT	C12N	15/13	X	
AF	EP 239,400	03/26/1987	Europe	C12N	15/00	X	
AG	WO 89/09622	10/19/1989	PCT	A61K	39/395	X	
AH	EP 338,745	03/01/1995	Europe	C12N	15/00	X	
 ΑI	EP 332,424	03/08/1989	Europe	C12N	15/00	X	
AJ	WO 89/09789	10/19/1989	PCT	C07K	15/00	X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	The state of the s
AK	B. Dietzschold, B., "Techniques For The Purification Of Rabies Virus, Its Subunits And Recombinant Products," <i>Laboratory Techniques in Rabies</i> , Meslin et al., (Eds.) World Health Organization, Geneva, pp. 175-80 (1996).
AL	D. C. Hooper, "Rabies Virus", Manual of Clinical Laboratory Immunology, Part II, 5th ed., N.R. Rose (Ed.), ASM Press, Wash. D.C., pp. 755-60 (1997).
AM	W.R. Pearson, et al., "Improved Tools For Biological Sequence Comparison", Proc. Natl. Acad. Sci. USA, 1988, 85, 2444-48.
AN	J. M. Champion, et al., "The Development Of Monoclonal Human Rabies Virus-Neutralizing Antibodies As A Substitute For Pooled Human Immune Globulin In The Prophylactic Treatment Of Rabies Virus Exposure", J. Immunol. Methods, 2000, 235, 81-90.
AO	B. Dietzschold, et al., "Biological Characterization Of Human Monoclonal Antibodies To Rabies Virus", J. Virol., 1990, 64, 3087-90.
AP	S. C. Cheung, et al., "A Recombinant Human Fab Expressed in Escherichia coli Neutralizes Rabies Virus", J. Virol., 1992, 66, No. 11, 6714-20.
AQ	B. H. Muller, et al., "Phage-displayed and Soluble Mouse scFv Fragments Neutralize Rabies Virus", J. Virol., 1997, 67, pages 221-33.
AR	H. Ikematsu, et al., "Clonal Analysis of a Human Antibody Response", J. Immunol., 1993, 150, pages 1325-37.
AS	R. F. Rando et al., "Production of Human Monoclonal Antibodies Against Rabies Virus", Curr. Top. Microbiol. Immunol., 1994, 187, 195-205.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

										Sheet 2 of 2
SUBSTITUT	E FORM		DEPARTMENT OI		1	Z. DOCKET 221US	r NO.		In	nt.'l. App. No.:
INFO	RMA	TION DISCLO	SURE STATI	EMENT					P	CT/US2004/018613
						ICANT: las C. Hoop	oer et al.		<u></u>	
						Filing Date ne 2004	:		- 1	ROUP ot Yet Assigned
			U.S. P.	ATENT DO	CUME	NTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	NAME CLASS SU			LASS FILING DATE APPROPRIAT	
			FOREIG	N PATENT	DOCU	MENTS			·•	
		DOCUMENT NUMBER	DATE	COUNT	TRY	CLASS	SUBC	SUBCLASS		RANSLATION ES NO
						<u> </u>				
		OTHER DOC	UMENTS (Inc.	luding Autho	or, Title,	Date, Pe	rtinent P	ages, E	tc.)	
	AT									p. 143 (CRC Press
	AU		I., "A Recombinar Rabies Virus Infe							protein Fails to
	AV	T. Paterson et al	., "Variation in Ig Human Anti-Rhe	G1 Heavy Cha	in Alloty	pe Does No	t Contribu	te to Diff	ference	
·		1 3 4 5 4 4 4 4	8,7,7,7							

A	J. Cruse et al., "Genetically Engineered Antibodies" in "Illustrated Dictionary of Immunology" p. 143 (CRC Press 1995).
· A	H. D. Foley et al., "A Recombinant Rabies Virus Expressing Vesicular Stomatitis Virus Glycoprotein Fails to Protect Against Rabies Virus Infection", Proc. Natl. Acad. Sci. USA, 2000, 97(26), 14680-85.
A	
A	M. Takekoshi et al., GenBank sequence ID 11275302 available at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=11275302.
A	A. Plückthun, "Antibody Engineering: Advances from the Use of <i>Escherichia Coli</i> Expression Systems", Biotechnology, 1991, 9, 545-551.
A	Report of the Sixth WHO Consultation on Monoclonal Antibodies In Rabies Diagnosis and Research, (WHO, 1990).
A	WHO Consultation on Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment, Geneva, (WHO, 2002).
В	M. Schnell <i>et al.</i> , "Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1", <i>Proc. Natl. Acad. Sci. USA</i> , 2000 , <i>97</i> (7), 3544-49.
В	C. A. Hanlon, <i>et al.</i> , "Experimental Utility of Rabies Virus-Neutralizing Human Monoclonal Antibodies in Post- Exposure Prophylaxis, Vaccine, 2001 , <i>19</i> , 3834-42.
В	B. Dietzschold, et al., "Development of a cocktail of human recombinant anti-rabies virus monoclonal antibodies for post-exposure treatment of human rabies", XIII International Meeting On Research Advanced and Rabies Control in the Americas, November 3-8, 2002, Oaxaca City, Mexico (abstract; due to poor legibility of the copy a transcript of the abstract is also included).
В	C.L. Schumacher, et al., "Inhibition of Immune Responses Against Rabies Virus by Monoclonal Antibodies Directed Against Rabies Virus Antigens", Vaccine, 1992, 01, 754-60.
В	
В	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 8321-221US

Int.'l. App. No.:

PCT/US2004/018613

INFORMATION DISCLOSURE STATEMENT

APPLICANT:

Douglas C. Hooper et al.

Int.'l. Filing Date: 10 June 2004

GROUP

Not Yet Assigned

			U.S. PAT	ENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF
	AA AB	US 6,890,532	05/10/2005	Hooper et al.			APPROPRIATE)
	AC		08/21/2003	Hooper et al.	424	147.1	
	AD	US 2003/0165507 US 2004/0013672	09/04/2003	Hooper et al.	424	159.1	
		05 2004/00136/2	01/22/2004	Hooper et al.	424	147.1 159.1	

FOREIGN PATENT DOCUMENTS

		TUREIG	N PATENT DOCU	MENTS			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
AJ	EP 332,424 WO 89/09789	10/28/1993 03/26/1987 10/19/1989 03/01/1995 03/08/1989 10/19/1989	PCT Europe PCT Europe Europe PCT	C12N C12N A61K C12N C12N C07K	15/13 15/00 39/395 15/00 15/00	YES X X X X X X X	NO NO
\mathbf{O}	THED DOOR	3 (7)					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	B. Dietzschold, B., "Techniques For The Purification Of Paking VI
	111	B. Dietzschold, B., "Techniques For The Purification Of Rabies Virus, Its Subunits And Recombinant Products," D. C. Hooper, "Rabies Virus" Manual Color of Rabies World Health Organization Geneva and 175 of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus, "Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Color of Rabies Virus, "Manual Color of Rabies Virus," Manual Color of Rabies Virus, "Manual Colo
	4.5	Lautoratory Techniques in D. 1: 15 Manual of Rables Virus Its Subunits A 15
- 1	AL	D. C. Hooper, "Rabies Virus" M. Meshi et al., (Eds.) World Health Organization Genevation and Products,"
		Press, Wash D.C. 757 (Manual of Clinical Laboratory Immunology, Press, U.S. 175-80 (1996).
1	AM	D. C. Hooper, "Rabies Virus", Manual of Clinical Laboratory Immunology, Part II, 5th ed., N.R. Rose (Ed.), ASN W.R. Pearson, et al., "Improved Tools For Biological Sequence Comparison", Proc. Natl. Acad. Sci. USA, 1988, J. M. Champion, et al. "The Daysless of the State of the Comparison", Proc. Natl. Acad. Sci. USA, 1988, J. M. Champion, et al. "The Daysless of the State of the Comparison", Proc. Natl. Acad. Sci. USA, 1988,
1		85, 2444-48. **Improved Tools For Biological Sequence Comparison". Proc. Natl. Acad. S. 1789-
	AN	55, 2444-48. Sci USA 1989
1	TIN	J. M. Champion, et al., "The Development OSM
1		J. M. Champion, et al., "The Development Of Monoclonal Human Rabies Virus-Neutralizing Antibodies As A Immunol. Methods, 2000, 235, 81,00
		Immunol, Methods 2000, 225, 21, 22
J	AO ¯	Substitute For Pooled Human Immune Globulin In The Prophylactic Treatment Of Rabies Virus Exposure", J. B. Dietzschold et al. "Pieles in 16"
		1990 64 3007 00
	AP	B. Dietzschold, et al., "Biological Characterization Of Human Monoclonal Antibodies To Rabies Virus", J. 1990, 64, 3087-90. S. C. Cheung, et al., "A Recombinate II.
		S. C. Cheung, et al., "A Recombinant Human Fab Expressed in Escherichia coli Neutralizes Rabies Virus", J. Virol. Virol., 1992, 66, No. 11, 6714-20. B. H. Muller et al. "Phase discharge in the second of the seco
	40	Virol., 1992, 66, No. 11, 6714-20
1 .	AQ	B. H. Muller, et al., "Phage-displayed and S. L. L.
		1997, 67, pages 221-33
	AR	B. H. Muller, et al., "Phage-displayed and Soluble Mouse scFv Fragments Neutralize Rabies Virus", J. 1997, 67, pages 221-33. H. Ikematsu, et al., "Clonal Analysis of a Human Antibody Response", J. Immunol., 1993, 150, pages 1325-37. Immunol., 1994, 187, 195-205.
T	AS	R. F. Pande, J. M., Cional Analysis of a Human Antibody Response." J. L.
1	1	R. F. Rando et al., "Production of Human Monoclonal Antibodies Against Rabies Virus", Curr. Top. Microbiol. Immunol., 1994, 187, 195-205.
		immunol., 1994, 187, 195-205.
AMINED		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		•								Sheet 2 of 2
SUBSTITUT	E FORM		DEPARTMENT OI ENT AND TRADE		ATTY 8321-2	. DOCKET 221US	'NO.		In	nt.'l. App. No.:
INFO	RMA]	TION DISCLOS	SURE STATI	EMENT					P	CT/US2004/018613
						ICANT: as C. Hoop	er et al.			
						Filing Date ne 2004				ROUP ot Yet Assigned
			U.S. P.	ATENT DO	CUME	NTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME CLASS SUBCLA			ASS	FILING DATE (IF APPROPRIATE)	
			FOREIG	N PATENT I	DOCUI	MENTS				
		DOCUMENT NUMBER	DATE	COUNT	RY	CLASS	SUBC	SUBCLASS		RANSLATION ES NO
						1				
		OTHER DOCU	MENTS (Inc.	luding Author	r, Title,	Date, Pe	rtinent P	ages, E	tc.)	
	ΑТ	J. Cruse et al., "G 1995).	enetically Engin	eered Antibodie	s" in "Ill	ustrated Di	ctionary o	f Immuno	logy"	p. 143 (CRC Press
	AU		D. Foley et al., "A Recombinant Rabies Virus Expressing Vesicular Stomatitis Virus Glycoprotein Fails to tect Against Rabies Virus Infection", Proc. Natl. Acad. Sci. USA, 2000, 97(26), 14680-85.							

AT	J. Cruse et al., "Genetically Engineered Antibodies" in "Illustrated Dictionary of Immunology" p. 143 (CRC Press 1995).
AU	H. D. Foley et al., "A Recombinant Rabies Virus Expressing Vesicular Stomatitis Virus Glycoprotein Fails to Protect Against Rabies Virus Infection", Proc. Natl. Acad. Sci. USA, 2000, 97(26), 14680-85.
AV	T. Paterson et al., "Variation in IgG1 Heavy Chain Allotype Does Not Contribute to Differences in Biological Activity of Two Human Anti-Rhesus (D) Monoclonal Antibodies", Immunotechnology, 1998, 4(1), 37-47.
AW	M. Takekoshi et al., GenBank sequence ID 11275302 available at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=11275302.
AX	A. Plückthun, "Antibody Engineering: Advances from the Use of <i>Escherichia Coli</i> Expression Systems", Biotechnology, 1991 , <i>9</i> , 545-551.
AY	Report of the Sixth WHO Consultation on Monoclonal Antibodies In Rabies Diagnosis and Research, (WHO, 1990).
AZ	WHO Consultation on Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment, Geneva, (WHO, 2002).
BA	M. Schnell et al., "Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1", Proc. Natl. Acad. Sci. USA, 2000, 97(7), 3544-49.
BB	C. A. Hanlon, et al., "Experimental Utility of Rabies Virus-Neutralizing Human Monoclonal Antibodies in Post- Exposure Prophylaxis, Vaccine, 2001, 19, 3834-42.
ВС	B. Dietzschold, et al., "Development of a cocktail of human recombinant anti-rabies virus monoclonal antibodies for post-exposure treatment of human rabies", XIII International Meeting On Research Advanced and Rabies Control in the Americas, November 3-8, 2002, Oaxaca City, Mexico (abstract; due to poor legibility of the copy a transcript of the abstract is also included).
BD	C.L. Schumacher, et al., "Inhibition of Immune Responses Against Rabies Virus by Monoclonal Antibodies Directed Against Rabies Virus Antigens", Vaccine, 1992, 01, 754-60.
BE	"Rabies Vaccines. WHO Position Paper", Weekly Epidemological Record, 2002, 77, 109-20 (WHO, 2002).
BF	B. Dietschold, et al., "New Approaches to the Prevention and Eradication of Rabies", Expert Rev. Vaccines, 2003, 2(3), 89-96.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.